Carrollton-based biotech company Gradalis has appointed Eric Hall to CFO effective, according to a news release. Hall will start in the position effective Jan. 1.
"We are pleased to welcome Eric, a highly accomplished biopharmaceutical executive to Gradalis' leadership team," Steve Engle, CEO of Gradalis, said in the release. "His addition is very timely as Gradalis prepares to initiate a Phase 3 trial designed for product registration of our personalized immunotherapy, Vigil, in patients with ovarian cancer."
Hall has over 30 years of experience serving as CFO and COO for a variety of companies. Since 2019, he has helped California-based companies RAPT Therapeutics, ALX Oncology and Connect Biopharma and New York-based Elevation Oncology with their IPOs.
"I am excited to join Gradalis at this key inflection point and help the team build on the significant clinical, regulatory and manufacturing achievements to date," Hall said in the release. "I look forward to working with the seasoned Gradalis team to create long-term value for our shareholders and achieve our mission."
Founded in 2003, Gradalis is a private company that develops immunotherapies for ovarian and other cancers. The company has a manufacturing facility in Carrolton.
In April 2018, Gradalis raised $43.9 million from a group of investors.
